zanzalintinib + nivolumab + ipilimumab

**zanzalintinib + nivolumab + ipilimumab** is an investigational combination regimen composed of three agents: zanzalintinib, nivolumab, and ipilimumab. - **Zanzalintinib** is an experimental small molecule tyrosine kinase inhibitor (TKI), targeting multiple kinases involved in tumor growth and angiogenesis (including MET, AXL, and VEGF receptors). - **Nivolumab** is a monoclonal antibody inhibitor of programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to enhance T cell antitumor activity[2][3][5]. - **Ipilimumab** is a monoclonal antibody inhibitor of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also an immune checkpoint inhibitor that stimulates an immune response against tumors[3][5]. The combination is designed to potentiate antitumor immune responses through dual checkpoint blockade (PD-1, CTLA-4) plus targeted tumor inhibition (TKI component). Clinical trials are exploring this regimen for various cancers, including renal cell carcinoma (as referenced by use of similar triple combinations in clinical trials)[3].